Urovant Sciences (NASDAQ:UROV) shares are trading higher on Friday after the company late Thursday announced Sumitovant Biopharma will acquire the remaining stake in the company for $16.25 per share.
Urovant Sciences is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's pipeline products include Overactive Bladder (OAB), OAB in Men with Benign Prostatic Hyperplasia (BPH), and IBS-Associated Pain.
Urovant Science shares traded up 93.78% at $16.04 on Friday during the time of publication. The stock has a 52-week high of $16.08 and a 52-week low of $6.55.